Dapirolizumab is a humanized monoclonal antibody designed to target and neutralize CD40 ligand (CD40L), a protein involved in immune system activation. Its primary application lies in the treatment of autoimmune diseases, particularly systemic lupus erythematosus (SLE). By blocking the interaction between CD40L and its receptor CD40 on B cells and antigen-presenting cells, dapirolizumab helps reduce abnormal immune responses that drive inflammation and tissue damage in lupus. This antibody has been investigated in clinical trials to evaluate its ability to decrease disease activity, reduce flare frequency, and minimize reliance on broad immunosuppressive therapies. It shows potential in improving hematological parameters and reducing autoantibody production, which are key challenges in lupus management. Due to its targeted mechanism, dapirolizumab offers a more specific immunomodulatory approach with a potentially improved safety profile compared to conventional treatments.